Role of hepatic iron in non-alcoholic steatohepatitis

Hepatology Research

Volumn 39, Issue 3, 2009, Pages 213-222

  Sumida, Yoshio ^a   Yoshikawa, Toshikazu ^b   Okanoue, Takeshi ^c  

^a Nara City Hospital   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c Saiseikai Suita Hospital   (Japan)

Author keywords

Insulin resistance; Iron; Non alcoholic steatohepatitis; Nonalcoholic fatty liver disease; Oxidative stress; Phlebotomy

Indexed keywords

AMINOTRANSFERASE; FERRITIN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; HEMOJUVELIN; HEPCIDIN; INSULIN; IRON; REACTIVE OXYGEN METABOLITE; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC ASSOCIATION; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; HYPERFERRITINEMIA; INSULIN RESISTANCE; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON RESTRICTION; IRON STORAGE; LIPID PEROXIDATION; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 69249233513     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00442.x     Document Type: Review

References (95)

1. Lee KS, Buck M, Houglum K et al. Activation of hepatic stellate cells by TGFα and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461-8.
2. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Non-alcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-8.
3. Day C, James O. Steatohepatitis: A tale of two "hits"? (editorial). Gastroenterology 1998; 114: 842-5.
4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
5. George DK, Goldwurm S, Macdonald GA et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-18.
6. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic liver disease. J Hepatol 2003; 38: 32-8.
7. Okanoue T, Yamauchi N, Furutani M et al. Predictors of nonalcoholic steatohepatitis in Japanese patients: Thioredoxin and NASH. In: Okita K, ed. NASH and Nutritional Therapy. Tokyo: Springer, 2005; 64-72.
8. Younossi ZM, Gramlich T, Bacon BR et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-50.
9. Angulo P, Keach JC, Batts KP et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-62.
10. Chitturi S, Weltman M, Farrell GC et al. HFE mutations, hepatic iron, and fibrosis: Ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002; 36: 142-9.
11. Duseja A, Das R, Nanda M et al. Nonalcoholic steatohepatitis in Asian Indians is neither associated with iron overload nor with HFE gene mutations. World J Gastroenterol 2005; 11: 393-5.
12. Sumida Y, Nakashima T, Yoh T et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. Liver 2001; 21: 295-9.
13. Cairo G, Tacchini L, Recalcati S et al. Effect of reactive oxygen species on iron regulatory protein activity. Ann N Y Acad Sci 1998; 851: 179-86.
14. Haile DJ. Regulation of genes of iron metabolism by the iron-response proteins. Am J Med Sci 1999; 318: 230-40.
15. Leclercq IA, Farrell GC, Field J et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-75.
16. Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003; 5: 18-25.
17. Fargion S, Mattioli M, Fracanzani AL et al. Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 2448-55.
18. Bonkovsky HL, Jawaid Q, Tortorelli K et al. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-9.
19. Nelson JE, Bhattacharya R, Lindor KD et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 2007; 46: 723-9.
20. Duseja A, Das A, Das R et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci 2007; 52: 2368-74.
21. Deguti MM, Sipahi AM, Gayotto LC et al. Lack of evidence for the pathogenic role of iron and HFE gene mutations in Brazilian patients with nonalcoholic steatohepatitis. Braz J Med Biol Res 2003; 36: 739-45.
22. Yamauchi N, Itoh Y, Tanaka Y et al. Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE mutation in Japanese patients with nonalcoholic steatohepatitis. J Gastroenterol 2004; 39: 654-60.
23. Sohda T, Yanai J, Soejima H et al. Frequencies in the Japanese population of HFE gene mutations. Biochem Genet 1999; 37: 63-8.
24. Fernandez-Real JM, Lopez-Bermejo Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 2002; 51: 2348-54.
25. Houstis N., Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006; 440: 944-8.
26. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 2006; 55: 1042-5.
27. Niederau C, Berger M, Stremmel W et al. Hyperinsulinemia in non-cirrhotic haemochromatosis: Impaired hepatic insulin degradation? Diabetologia 1984; 26: 441-4.
28. Fargion S, Dongiovanni P, Guzzo A et al. Iron and insulin resistance. Aliment Pharamacol Ther 2005; 22: S61-3.
29. Potashnik R, Kozlovsky N, Ben-Ezra S et al. Regulation of glucose transport and GLUT-1 expression by iron chelators in muscle cells in culture. Am J Physiol 1995; 269: E1052-8.
30. Tanner LI, Lienhard GE. Insulin elicits a redistribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987; 262: 8975-80.
31. Davis RJ, Corvera S, Czech MP. Insulin stimulates cellular iron uptake and causes the redistribution of intracellular transferrin receptors to the plasma membrane. J Biol Chem 1986; 261: 8708-11.
32. Mendler MH, Turlin B, Moirand R et al. Insulin resistance-associated hepatic iron overload. Gastroenterology 1999; 117: 1155-63.
33. Sanyal AJ, Campbell-Sargent C, Mirshahi F et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
34. Ferrarini E. Insulin resistance, iron, and the liver. Lancet 2000; 355: 2182.
35. Haap M, Fritsche A, Mensing HJ et al. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med 2003; 139: 869-71.
36. Iwasaki T, Nakajima A, Yoneda M et al. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 2005; 28: 2486-91.
37. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care 2004; 27: 2422-8.
38. Elsammak M, Refai W, Elsawafi A et al. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Curr Med Res Opin 2005; 21: 527-34.
39. Shaheen M, Echeverry D, Oblad MG et al. Hepatitis C: Metabolic syndrome, and inflammatory markers: Results from the third national health and nutrition examination survey. Diabetes Res Clin Pract 2006; 16: 320-6.
40. Furutani M, Nakashima T, Sumida Y et al. Insulin resistance/β cell function and serum ferritin level in non-diabetic patients with hepatitis C virus infection. Liver Int 2003; 23: 294-9.
41. Sumida Y, Kanemasa K, Fukumoto K et al. Hepatic iron accumulation may be associated with insulin resistance in patients with chronic hepatitis C. Hepatol Res 2007; 37: 932-40.
42. Marchesini G, Brizi M, Bianchi G et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
43. Sumida Y, Fukumoto K, Yoshida N et al. Iron accumulation and phlebotomy in nonalcoholic fatty liver disease (NAFLD). Jpn Pharmacol Ther 2007; 35: S277-81.
44. Sumida Y, Kanemasa K, Fukumoto K et al. Correlation of hepatic steatosis with body mass index, serum ferritin level, and hepatic fibrosis in Japanese patients with chronic hepatitis C. Hepatol Res 2007; 37: 263-9.
45. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-36.
46. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10.
47. Ganz T. Hepcidin, key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783-8.
48. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Sicience 2004; 306: 2090-3.
49. Park CH, Valore EV, Waring AJ et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001; 276: 7806-10.
50. Nemeth E, Rivera S, Gabayan V et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory horomine hepcidin. J Clin Invest 2004; 113: 1271-6.
51. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002; 110: 1037-44.
52. Nagashima M, Kudo M, Chung H et al. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Hepatol Res 2006; 36: 288-93.
53. Fujita N, Sugimoto R, Takeo M et al. Hepcidin expression in the liver. Relatively low level in patients with chronic hepatitis C. Mol Med 2007; 13: 97-104.
54. Fujita N, Sugimoto R, Motonishi S et al. Patients with chronic hepatitis C achieving a sustained response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol (in press).
55. Aoki CA, Rossaro L, Ramsamooj R et al. Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C. J Clin Gastroenterol 2005; 39: 71-4.
56. Nishina S, Hino K, Korenaga M et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 2008; 134: 226-38.
57. Bridle K, Cheung TK, Murphy T et al. Hepcidin is down-regulated in alcoholic liver injury: Implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res 2006; 30: 106-12.
58. Ohtake T. Saito H, Hosoki Y et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res 2007; 31: 2S-8S.
59. Le Guenno G, Chanséaume E, Ruivard M et al. Study of iron metabolism disturbances in an animal model of insulin resistance. Diabetes Res Clin Prac 2007; 77: 363-70.
60. Bekri S, Gual P, Anty R et al. Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. Gastroenterology 2006; 131: 788-96.
61. Mascitelli L, Pezzetta F. Does hepcidin expression have a role in iron-related hepatic injury in patients with non-alcoholic steatohepatitis?. Hepatol Res 2007; 37: 775.
62. Aigner E, Theurl I, Theurl M et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 2008; 87: 1374-83.
63. Aigner E, Theurl I, Haufe H et al. Copper availability contributes to iron perturbations in human nonalcoholic fatty liver disease. Gastroenterology 2008; 135: 680-8.
64. Barabino A. Helicobacter pylori-related iron deficiency anemia: A review. Helicobacter 2002; 7: 71-5.
65. Ufour C, Brisigotti M, Fabretti G et al. Helicobacter pylori gastric infection and sideropenic refractory anemia. J Pediatr Gastroenterol Nutr 1993; 17: 225-7.
66. Choe YH, Kim SK, Son BK et al. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999; 4: 135-9.
67. Annibale B, Marignani M, Monarca B et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann Intern Med 1999; 131: 668-72.
68. Sugiyama T, Tsuchida M, Yokota K et al. Improvement of long-standing iron-deficiency anemia in adults after eradication of Helicobacter pylori infection. Intern Med 2002; 41: 491-4.
69. Marignani M, Angetti S, Bordi C et al. Reversal of long-standing iron deficiency anemia after eradication of infection. Scand J Gastroenterol 1997; 115: 268-74.
70. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: A review of the evidence. Am J Gastroenterol 2005; 100: 453-9.
71. Ruiz B, Rood JC, Fontham ET et al. Vitamin C concentration in gastric juice before and after anti- Helicobacter pylori treatment. Am J Gastroenterol 1994; 89: 533-9.
72. Nakao K, Imoto I, Ikemura N et al. Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. Am J Gastroenterol 1997; 92: 1005-11.
73. Nakao K, Imoto I, Gabazza EC et al. Gastric juice levels of lactoferrin levels and Helicobacter pylori infection. Scand J Gastroenterol 1997; 32: 530-4.
74. Husson MO, Legrand D, Spik G, Leclerc H. Iron acquisition by Helicobacter pylori: Importance of human lactoferrin. Infect Immun 1993; 61: 2694-7.
75. Pellicano R, Rizzetto M. Is hepcidin the bridge linking Helicobacter pylori and anemia of chronic infection? A research proposal. Panminerva Med 2004; 46: 165-9.
76. Beutler E. Hepcidin mimetics from microorganisms? A possible explanation for the effect of Helicobacter pylori on iron homeostasis. Blood Cells Mol Dis 2007; 38: 54-5.
77. Sumida Y, Kanemasa K, Yamaoka Y et al. The influence of Helicobacter pylori infection on iron accumulation in hepatitis C. Liver Int 2006; 26: 827-33.
78. Otogawa K, Kinoshita K, Fujii H et al. Erythrophagocytosis by liver macrophages (Kupffer cells) promotes oxidative stress, inflammation, and fibrosis in a rabbit model of steatohepatitis: Implications for the pathogenesis of human nonalcoholic steatohepatitis. Am J Pathol 2007; 170: 967-80.
79. Valenti L, Dongiovanni P, Piperno A et al. Alpha 1-antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage. Hepatology 2006; 44: 857-64.
80. Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2005; 100: 1072-81.
81. Kawanaka M, Mahmood S, Niiyama G et al. Control of oxidative stress and reduction in biochemical markers by vitamin E treatment in patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2004; 29: 39-41.
82. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-307.
83. Yano M, Hayashi H, Yoshioka K et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: A multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 2004; 39: 570-4.
84. Sumida Y, Kanemasa K, Fukumoto K et al. Effects of dietary iron reduction versus phlebotomy on patients with chronic hepatitis C: results from a randomized, controlled trial in 40 Japanese patients. Intern Med 2007; 46: 637-42.
85. Facchini FS, Hua NW, Stoohs RA. Effect of iron reduction in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 931-9.
86. Valenti L, Fracanzani AL, Fargion S et al. Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. Gastroenterology 2003; 124: 866-7.
87. Sumida Y, Kanemasa K, Fukumoto K et al. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol Res 2006; 36: 315-21.
88. Riquelme A, Soza A, Nazal L et al. Histological resolution of steatohepatitis after iron depletion. Dig Dis Sci 2004; 49: 1012-15.
89. Valenti L, Fracanzani AL, Dongiovanni P et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: Evidence from a case-control study. Am J Gastroenterol 2007; 102: 1-8.
90. Fernadez-Real JM, Penarroja G, Castro A et al. Bloodletting in high-ferritin diabetes: Effect on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-4.
91. Facchini FS. Effects of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998; 21: 2190.
92. Guillygomarc'h A, Mendler MH, Moirand R et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001; 35: 344-9.
93. Piperno A, Vergani A, Salvioni A et al. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int 2004; 24: 471-6.
94. Yamamoto M, Iwasa M, Iwata K et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007; 22: 498-503.
95. Iwasa M, Iwata K, Kaito M et al. Efficacy of long-term dietary restriction of total calories, fat, iron, and protein in patients with chronic hepatitis C virus. Nutrition 2004; 20: 368-71.